NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
Position in DNLI — Denali Therapeutics Inc.
CIK 921739
PHILADELPHIA, PA
Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$56,796,524
+$54,597,664 QoQ
Shares Held
2,208,263
+1828.2% QoQ
Ownership
1.38%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#22
of 290 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 97%
Shared 0%
None 3%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NOMURA ASSET MANAGEMENT INTERNATIONAL INC. holds $1,804,143,507 across 92 Biotechnology names. DNLI ranks #12 (3.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
568,371 | $179,656,389 | |
| 2 | TVTX |
Travere Therapeutics, Inc.
|
2,812,514 | $159,778,920 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
539,407 | $132,030,651 | |
| 4 | IONS |
Ionis Pharmaceuticals Inc
|
1,300,392 | $103,108,081 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
1,183,799 | $92,655,947 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
300,193 | $90,367,098 | |
| 7 | MIRM |
Mirum Pharmaceuticals, Inc.
|
752,044 | $88,041,791 | |
| 8 | CYTK |
Cytokinetics Inc
|
961,815 | $81,937,019 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $56,796,524 | 2,208,263 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $2,198,860 | 114,524 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,774,709 | 107,493 | Shares | Defined | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||